AAAAAA
Results:
1-7
|
Results: 7
Authors:
Hynes, NE
Lane, HA
Citation: Ne. Hynes et Ha. Lane, Myc and mammary cancer: Myc is a downstream effector of the ErbB2 receptortyrosine kinase, J MAMMARY G, 6(1), 2001, pp. 141-150
Authors:
Neve, RM
Lane, HA
Hynes, NE
Citation: Rm. Neve et al., The role of overexpressed HER2 in transformation, ANN ONCOL, 12, 2001, pp. 9-13
Authors:
Lane, HA
Motoyama, AB
Beuvink, I
Hynes, NE
Citation: Ha. Lane et al., Modulation of p27/Cdk2 complex formation through 4D5-mediated inhibition of HER2 receptor signaling, ANN ONCOL, 12, 2001, pp. 21-22
Authors:
Neve, RM
Sutterluty, H
Pullen, N
Lane, HA
Daly, JM
Krek, W
Hynes, NE
Citation: Rm. Neve et al., Effects of oncogenic ErbB2 on G1 cell cycle regulators in breast tumour cells, ONCOGENE, 19(13), 2000, pp. 1647-1656
Authors:
Lane, HA
Beuvink, I
Motoyama, AB
Daly, JM
Neve, RM
Hynes, NE
Citation: Ha. Lane et al., ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: Receptor overexpression does not determine growth dependency, MOL CELL B, 20(9), 2000, pp. 3210-3223
Authors:
Olayioye, MA
Neve, RM
Lane, HA
Hynes, NE
Citation: Ma. Olayioye et al., The ErbB signaling network: receptor heterodimerization in development andcancer, EMBO J, 19(13), 2000, pp. 3159-3167
Authors:
Daly, JM
Olayioye, MA
Wong, AML
Neve, R
Lane, HA
Maurer, FG
Hynes, NE
Citation: Jm. Daly et al., NDF/heregulin-induced cell cycle changes and apoptosis in breast tumour cells: role of PI3 kinase and p38 MAP kinase pathways, ONCOGENE, 18(23), 1999, pp. 3440-3451
Risultati:
1-7
|